Replay available

Kamada (NASDAQ:KMDA) Q2 2020 Earnings Call

Kamada (NASDAQ:KMDA) Q2 2020 earnings call, held 2020-08-12. Watch the replay and read the transcript on 6ix.

Wed, August 12, 2020 at 8:30 AMendedReplay
Kamada (NASDAQ:KMDA) Q2 2020 Earnings Call
Company
Kamada Ltd. (NASDAQ:KMDA)
Period
Q2 2020 earnings call
Date
Wed, Aug 12, 2020, 8:30 AM ET
Replay
Watch the replay on this page · 38 min
Results news release
Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position   · Wed, Aug 12, 2020

On 6ix: 6ix.com/event/kamada-ltd-kmda-q2-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Thank you for standing by. This is the conference operator. Welcome to the Kamada Limited second quarter 2020 earnings conference call. As a reminder, all participants are in listen only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then one on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star and zero. I would now like to turn the conference over to Troy Williams of LifeSci Advisors. Please go ahead.

0:36 Troy Williams Thank you and good morning, everyone. This is Troy Williams of LifeSci Advisors. Thank you all for participating in today's call. Joining me from Comida are Amir London, Chief Executive Officer, and Chaime Orlev, Chief Financial Officer. Earlier this morning, Comida announced financial results for the three and six months into June 30, 2020. If you have not received this news release, please go to the investor's page of the company's website at www.comida.com. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Comida. I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitation the company's forms 20F and 6K.

1:28 which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 12, 2020. AMADA undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that said, It is my pleasure to turn the call over to Amir London, CEO. Amir?

2:05 Thank you, Troy. My thanks also to our investors and analysts for your interest in Kamada and for participating in today's call. I hope you all are keeping safe and healthy in these challenging times. Let me begin by discussing the significant progress we have achieved in the development of our plasma-derived immunoglobulin product, as a potential therapy for COVID-19 disease. Following our announcement in June of being the first company globally with an availability of a COVID-19 IgG product for compassionate youth treatment in Israel, earlier this week we announced initiation of a Phase 1-2 clinical study in Israel. This is an open-label, single-arm, multi-central study to assess the safety, pharmacokinetics, and pharmacodynamics of our IgG product in 12 hospitalized non-ventilated COVID-19 patients with pneumonia.

3:07 Our product has also been evaluated for SARS-CoV-2 neutralization activity and the preliminary results are highly encouraging and suggest potential high neutralization titer. Lastly, we intend to further explore the potential of our IgG product to prevent COVID-19 disease in Healthy Subjects at Risk in a Separate Study. We are very excited by this meaningful progress, and we believe our product has the potential to be an effective treatment for hospitalized non-ventilated COVID-19 patients with pneumonia, and we look forward to the results of this trial later this year. As a reminder, this milestone is part of our global collaboration agreement established in April 2020 with Cadrion Biopharma for the development, manufacturing, and distribution of our IgG product as a potential treatment for COVID-19 patients. Pursuant to the collaboration between the two companies, Cadrion is responsible for the collection of COVID-19 convalescent plasma from U.S. recovered patients. Cadrion is already collecting the plasma through its plasma business unit, CAD Plasma, at 23 FDA approved centers across the United States.

4:34 We intend to expand our COVID-19 clinical development program to the U.S. and plan to conduct a pre-IND meeting with the U.S. FDA during the current quarter in order to obtain FDA acceptance for our proposed clinical development program. If FDA clearance of the IND is received, Kamada and Kadrian intend to initiate the clinical program in the U.S. in early 2021. Moving on, I'd like to report that we are accelerating our commercial and business development efforts, and we are working to mitigate the effect of the planned transition of Glastonbury Manufacturing to Takeda during 2021. I am optimistic that our organic commercial growth as well as additional business development opportunities and many more. As a reminder, we anticipate revenues of approximately $65 million from sales of glasses to Takeda this year and in the range of $25 million to $50 million in 2021 based on Takeda supply needs. In addition, based on the agreement between the companies upon the initiation of sales of Galassia manufactured by Takeda, we will receive royalty payments from Takeda at a rate of 12% on net sales through August 2025 and

6:05 at a rate of 6% thereafter until 2040 with a minimum of $5 million annually for each of the years from 2022 to 2040. In addition to Glacia's contribution, we expect Kedrub's revenue and U.S. market share to continue to grow. As a reminder, Kedrub U.S. market share increased from approximately 10% in 2018 to approximately 20% in 2019, and it continues to grow. In addition, we anticipate continued strong contribution from our distributed product in Israel both existing products as well as new products which we will be launching in Israel during the next few years.

6:57 Going forward, we also expect meaningful growth from our existing proprietary IGG product portfolio as well as Glacia in the international markets outside of the U.S. Moreover, the contract manufacturing agreement we signed in late 2018 for an FDA-approved commercial stage specialty hyperimmunoglobulin product, which is currently in its technology transfer phase, is expected to have significant contribution to our plant utilization and growth starting in the beginning of 2023. In addition to all of that, we believe that our leading development programs, the IGG product for COVID-19 and the InHealth AAT, if approved have substantial market opportunities.

7:50 Beyond the significant existing internal potential growth catalyst, we intend to utilize our strong balance sheet to identify additional business development opportunities that leverage our expertise and manufacturing capabilities. We are optimistic about the future of our business, and we are confident that our actions will generate significant shareholder value. Let's now turn to the current status of our innovative Phase III clinical program for our propriety in Health AAT for the treatment of Alpha-1 antitrypsin deficiency. As you will recall, we've been recruiting patients into the Phase III trial in Europe through February 2020.

8:36 However, as we said on our last call in March, due to the effect of the COVID-19 pandemic on health care systems, Recruitment into the study was temporarily halted. I am pleased to report today that recruitment into the study restarted in June. As a reminder, INNOVATE is a randomized, double-blind, placebo-controlled, pivotal, phase three trial designed to assess the efficacy and safety of inhaled AAT in patients with alpha-1 deficiency and moderate lung disease. up to 250 patients will be randomized one-to-one to receive either inhaled AAT at a dose of 80 milligram once daily or placebo over two years of treatment. The primary endpoint of the INOVAIT trial is lung function measured by FEV1.

9:35 Secondary endpoints include changes in lung density as measured by CT scan as well as other parameters of Disease Severity, such as additional pulmonary functions, reservations rate, and six-minute walk test. Before I turn the call over to Chaime for his review of the second quarter and the first half of 2020 financial review, I'd like to take this opportunity and mention the recent changes in our Board of Directors, which were also announced this morning. First, I would like to thank Mr. Leon Riccanati for his contribution to Kamada as an investor, director, and chairman, an office he held for the last seven years.

10:25 His continued support and contribution to Kamada, and to myself personally, was invaluable. I believe that Ms. Lila Hasher Topilsky's nomination as Kamada's chairperson is indicative of Femi's confidence in the company's long-term growth prospects, market position, corporate strategy, and our solid management team. Over the past several months, since Lilakh's appointment to come on the board, she's made significant contribution, and I congratulate her on her appointment, and I look forward to our continued successful cooperation. As a background, the Femi Opportunity Fund is the leading private equity investor in Israel, and is Kamada's lead shareholder.

11:14 Lastly, I'm happy to welcome Professor Ari Shamis to Kamada's Board of Directors. Ari's extensive experience as a senior executive at leading hospitals in Israel will be important in strengthening our business, including our commercial product, as well as our clinical pipeline. Professor Shamis is a highly respected healthcare authority in Israel and we look forward to his significant contribution to Kamada. With that, I'll now ask Chaime to review our financial results. Chaime.

11:51 Thank you, Amir, and good day, everyone. We continue to be pleased with the momentum in our business, especially in light of the ongoing operating challenges posed by the COVID-19 pandemic. We demonstrated solid year-over-year top-line growth during the first six months of 2020. In the second quarter, total revenues were $33.1 million compared to $35.3 million for the second quarter of 2019. While this represents a decrease of 6% for the first six months of 2020, our total revenues of $66.4 million represented an increase of 7% as compared to the Thank you very much.

13:02 was also driven by a 28% year-over-year increase in sale of our distributed products. We expect our distributed products in Israel to continue to be an important driver of our growth prospects. Moreover, longer term, we anticipate that this segment will improve our overall gross margins. The company's business activity and commercial operation were affected by certain COVID-19 pandemic-related factors. and the company had taken several actions to ensure its manufacturing plant remains operational with limited disruption to its business continuity, even with the emergency regulation recently reinforced in Israel due to the pandemic.

13:48 Moreover, to date, we have not seen any meaningful supply shortages in the U.S. market for Glacier or Kedron, and we do not anticipate shortages in the foreseeable future. We also have not seen nor do we expect any significant supply shortages for a distributed product in Israel in the foreseeable future. While the COVID-19 related disruptions had various effects on the company's business activities, commercial operations, revenue, and operational expenses, as a result of the actions taken by the company to date, its overall result of operation for the first six months of 2020 and financial position as of June 30, 2020, were not particularly effective.

14:34 The company expects that its continued actions will allow meeting its annual revenue guidance. However, a number of COVID-19-related factors may still have an effect on the company's future financial position and results of operation. With that said, we are reiterating our previously provided full-year 2020 revenue guidance of between $132 million and $137 million. Turning to profitability, for the second quarter of 2020, total gross profit was $11.1 million compared to $13.6 million reported in the second quarter of 2019. Proprietary gross margins in the second quarter of 2020 were 43%, down 3 percentage points as compared to the second quarter of 2019.

15:28 This decrease is in line with our previous guidance of an annual three to five percentage point decrease, which is attributable to a change in sale product mix and reduced plant utilization. The different mix is a result of inventory management by our distributors and timing of our product shipments. Similar influence also impacted the distribution segment profitability this quarter. For the first half of this year, our total gross profit was $22.6 million and gross margins were 34%. This compares to $24.8 million of total gross profit and 40% margins in the first half of 2019.

16:15 Operating expenses, including research and development, sales and marketing, G&A, as well as other expenses, total $7.1 million in the second quarter of 2020. as compared to $7.2 million in the second quarter of 2019. For the first half of the year, these costs totaled $13.7 million compared to the $13.2 million in the first half of 2019. The COVID-19 related delay in enrollment in the company's pivotal Phase III Innovate clinical trial resulted in lower than expected increase in research and development expenses. As Amir noted, Enrollment in this trial has now resumed and we would expect our operating expenses to increase accordingly over the second half of 2020.

17:04 Our original guidance for annual research and development expense was for an expected 20 to 25% increase. Given the delay mentioned earlier, we currently expect a 15 to 17% increase for full year 2020 as compared to 2019. Moving on, net income was 3.5 million or 8 cents per share in the second quarter of 2020 as compared to net income of 6.1 million or 15 cents per share in the second quarter of 2019. For the six months of 2020, net income was 8.7 million or 20 cents per share as compared to net income of 11.1 million or 27 cents per share in the six months of 2019.

17:56 During the second quarter and first half of 2020, we continue to generate cash from operating activities and we maintain a strong balance sheet with a total of 104.7 million of cash, cash equivalents and short-term investments as of June 30th, 2020, as compared to 73.9 million at December 31, 2019. Part of the increase is related to the $25 million private placement with the Female Opportunity Fund closed earlier this year. That concludes our prepared remarks. We will now open the call for questions. Operator? Thank you. We will now begin the question and answer session.

18:43 To join the question queue, you may press star then 1 on your telephone keypad. You will hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then two. We will pause for a moment as callers join the queue. The first question is from Raj Denhoi of Jefferies. Please go ahead.

19:12 Hi, good morning. I wonder if maybe I could start with some of the reports during the quarter of The compassionate use of a plasma product from you guys in Israel to treat COVID patients. Anything you can offer anecdotally about the use so far and what you're seeing with the product?

19:30 Hi, Raj. Thank you for the question. Thank you for joining the call. There were a few treatments of compassionate use. The procedure in Israel is that this approval for compassionate use treatment goes between the medical center and the treating physician and the Minister of Health. So Kamada is not part of this process. We basically made the product available for the medical centers and they need to apply and get kind of a named patient approval for the treatment. So this is not data that is available to Kamada. The clinical study, which was started just recently, is sponsored by Karmada, and the data from that study, of course, will be available and will be shared in due time with the public.

20:31 As we announced earlier this week, we are encouraged by the neutralization data that we have seen in the different and all the assays that we are performing. And we just need to wait now, not too long before we have the data from the clinical study. Important to mention the clinical study is for the less severe patients, meaning not the one that got the compassionate use. The compassionate use was given to patients that were severely ill while the clinical study, as we just described, is for hospitalized but not ventilated patients. We believe that that's the right population for this type of treatment.

21:18 We believe that you need to catch those patients, if I can use this term, while they are highly viral but before their situation worsens significantly in order for the IgG to be effective.

21:35 That's helpful. You also mentioned that you're looking at the product as a preventative, potential preventative to COVID. Is there anything you can offer in terms of what that looks like? Is that a separate trial entirely, or how do we think about the timing of that?

21:48 Yes, this will be a separate trial. We are now in discussions with the regulators and the KOLs in regards to that study. It's going to be the same product, while the dosing might be different. We will be testing different doses in order to get to the optimal dose for preventive or prophylactic treatment compared to sick patients. Now, there are different approaches to that. You may think about the medical stuff. You may think about patients or people that are at high risk and have been exposed to a sick COVID patient, like a post-exposure prophylactic.

22:38 You may think about the elderly population. So there are different opportunities, different populations, which potentially meet this criteria. And we are in advanced discussions with different relevant parties on how to design that study and to what population.

23:00 That's helpful. Maybe just a couple more. So, you know, Kedrion is your partner. You mentioned, obviously, in the United States collecting plasma for you here. What has been the status of their collection efforts? You know, how successful have they been in actually collecting convalescent plasma? There's been some reports of it being somewhat more difficult, perhaps, to get supplies. So how is Kedrion faring?

23:24 So there's a good progress in the collection. You know, Kedrion has a large network. of plasma collection centers in the U.S. They've put most of those centers, they are included in the collection effort. This plasma, U.S. plasma, will be supplied to Kamada in order for us to initiate also our U.S. clinical program. So the plasma we are currently using for the Israeli study is plasma that was collected from convalescent patients in Israel. We moved very fast already in March in terms of working here in Israel with the local authorities on defining the path forward, working with the Israeli National Blood Bank on the collection. And this allowed us, if you may remember, in June to be the first company globally to announce availability of a plasma-derived COVID IgG, and also to be the first globally to initiate a clinical study. So we are very happy with the progress we've been making, and we believe that it's very high potential for a successful treatment for COVID-19 patients.

24:48 That's helpful. Maybe just one last one on the quarter. So the last couple of quarters now we've seen Distributed product sales being quite strong, you know, crested $10 million this quarter. I think, Jaime, you mentioned it's going to be a continued contributor at a higher rate here. So maybe just some background in terms of what's driving that higher revenue from distributed products over the short term. I realize there's other things coming longer term, but I'm more curious about what's been pushing it recently.

25:13 Yes. So over the last few years, we have been expanding our portfolio significantly. of distributed products for Israel and we've been signing quite a lot of new agreements for the Israeli market with different international partners. So some of it is new products that have been registered over the last two years and have been launched into the Israeli market. Some of it is an increase in the plasma-derived products or legacy products like IVIG that we've been selling in Israel for many years. There was additional stocking of IVIG Thank you very much. So we are very happy with the progress we are making with the distributed product in Israel, and we are very encouraged by the rate it's growing, also looking into the future, 2021 and beyond.

26:32 But for the second half of the year, we shouldn't assume it stays above $10 million. There was a little bit of perhaps higher sales this quarter, so maybe it falls back a little bit in the second half, you think?

26:43 Correct. I think you need to stick to what you just said. It's reiterating our full year projection, and we are on track to meet it. We've been telling investors and analysts over the years, don't judge us quarter by quarter, but look at our annual projection and annual performance. We've been very good in the last few years giving an annual projection and meeting it, and the same applies for this year, 2022.

27:14 Great. That's helpful. Thank you. The next question is from Kay Nakai of Chardon. Please go ahead.

27:25 Yes. Thanks for the IgG hyperimmune. What are you measuring for efficacy endpoints in the Phase I, II in Israel?

27:36 So currently – hi, Kay. How are you? So currently, you know, it's a Phase I, II study, so of course, We are measuring safety and we are looking also at PK and PD, pharmacokinetics and pharmacodynamics data. But also being an open label study, basically we will have data on each and every patient and we'll be also looking at number of hospitalized days and when the patient has been hopefully recovered and released from the hospital. But the official Endpoints, of course, are safety and some are PK and PD.

28:20 So just trying to extend that to the prophylactic use, do you have a sense from the regulatory authorities what you'd need to demonstrate in order for it to be used prophylactically?

28:38 Not yet. Like I answered the previous question, Profilactic or post-exposure prophylactic is definitely an area or a direction that we are interested in. This is part of the discussion that we are having internally and with the KOLs and with the treating physicians and we initiated also with authorities in order to have a clear path forward what will be required in terms of the path forward, the clinical, the medical, the regulatory path forward for potentially approval, future approval of prophylactic treatment. Is this PK data, things like that? All of it is in discussion.

29:27 Are you getting a sense that if you have... No safety issues and you can demonstrate some level of antibodies within some, I guess, relatively short period of time. This protection isn't that long lasting. Would that be sufficient in your view, at least today, to have something approved for prophylactic use?

29:59 We believe, and this is very preliminary what I'm just saying, this is not, I'm putting a disclaimer now, this has not been fully discussed and definitely approved or agreed with the regulators, but potentially having the ability to compare the PK data, the antibodies level of a prophylactic IgG to an active vaccine that will be approved, this could be a potential one way to look at the product. So definitely when you're looking at healthy individuals, it has to be some type of PK data because you're not treating sick patients. So this is one of the ways to look at it.

30:47 Alternatively, that could be a very large study that you are treating patients and then you see who gets sick and who doesn't get sick compared to some type of control group. This is another option, but again, it will depend on how the regulators would like to see such a path and a potential future approval.

31:09 Okay, that's helpful. Maybe switching to the operations side and the gross margin, how much lower should we expect that the gross margins will trend down to?

31:27 So we gave, Chaime, do you want to help me here?

31:29 We gave a projection of... Yeah, we gave a projection that three to five percentage points drop in gross margins in the proprietary sector as compared to last year. And we still stand behind that guidance.

31:51 And last year it was 46%.

31:56 Right, so I guess what I'm asking is that for this year, what happens as we kind of roll into the first half of next year?

32:09 So we think it's a little bit too early now to give an answer to that. We are expecting feedback from Takeda later this year in preparation for 2021. for what's going to be their demand. We mentioned it's going to be between $25 to $50 million in sales, and it depends on when the tech transfer of Glacia to Takeda will be completed and when they expect to have the FDA approval. This, of course, will have an impact on our 2021 projection. Also, a potential impact of the COVID-19 IgG. So there are a few items, a few things that need to be focused

32:53 Thank you very much.

33:24 Thank you very much.

33:54 Thank you. The next question is from Gadi Hassan, a private investor. Please go ahead. Hi, Amir. I have a question about the value that

34:24 I believe you have data as you are rolling up people and you will know in a few weeks what is the result. If the result will be satisfying, do you expect that we can see that you can start the compression treatment to do it with payment? to try to sell this treatment. Also, you don't have any yet an agreement to sell it as FDA approval or something like that. If you can sell it as a compassion treatment by payment before you have even begin the phase whatever you intend to do next year to start with the FDA, I don't know if it will be Again, you have to repeat the Phase 1-2, or maybe you will take this result and continue to Phase 2-3 in the United States.

35:33 Thank you.

35:34 Thank you, Gadi. I'll first answer the later part of your question. In regards to the U.S. path forward, so as we said, we are going to hold a pre-IMD meeting with the FDA this quarter. So all those issues will be raised and will be discussed as part of that process. And then we'll have better clarity and we will announce what the plan forward in terms of the needed studies. In terms of your question regarding paid compassionate treatment, so it's a little bit too early right now to give you an answer for that. It's an option, but we will need to wait for the data and to have the discussions with the relevant authorities before we can provide any feedback about it.

36:37 Okay, thank you very much. This concludes the question and answer session. I would like to turn the call back over to Amir London for any closing remarks.

36:51 Thank you very much. In summary, we are pleased with how our business performed in the first half of 2020, especially as the global COVID-19 pandemic persisted. We have an extremely strong balance sheet and the fundamentals of our business are solid. Our IGG product development program for the treatment of COVID-19 continues to advance very fast. In addition, we continue to drive strategic growth from our core business including Lassia, Cadrav, and our distributed products in Israel. We anticipate that our business development activities will have a meaningful role in our future growth and are also very excited about the potential of our innovative Pivot Alphae 3 trial for our unique Inherent AET program and are encouraged that enrollment has now been resumed.

37:47 We remain highly confident in Canada's long-term outlook for success. Thank you for joining us on today's call and we look forward to providing you with further updates on our progress in the coming months. We hope all of you stay healthy and safe. Thank you very much. This concludes today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.

Follow Kamada Ltd. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Troy Williams

LifeSci Advisors

Amir London

Chief Executive Officer, Kamada Limited

Chaime Orlev

Chief Financial Officer, Kamada Limited

Raj Denhoi

Analyst, Jefferies

Kay Nakai

Analyst, Chardon

Gadi Hassan

Private Investor

More from Kamada Ltd.